Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: pull incentive

Prospecting for New Antibiotics

Posted on November 25, 2016 by Harald — No Comments ↓

The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA expedited review and more.  In addition, FDA made it quite easy to garner the label.  Continue reading Prospecting for New Antibiotics→

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...
Posted in Did you know...?, QIDP Antibiotics, The News, The Viewpoint | Tagged AAI-101, ACH-975, Adhaogen, Affinium, antibiotic blog, antibiotic pipeline, AstraZeneca, Chiron, Crestone, Debiopharm, Entasis, ETX-0914, FabI, FDA, FtsZ, GSK, GSK-2140944, GSK-2251052, Harald Reinhart, LpxC inhibitor, MAT-2501, Matinas, MCB-3837, Morphochem, moxifloxacin, Novartis, novel MoA, novel MoA antibiotics, oxaquin, PDF inhibitor, pull incentive, push-pull incentive, QIDP, systemically active QIDP antibiotics, Taxis Pharma, topoisomerase II inhibitor, tRNA synthase inhibitor, TXA-709 | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • Some Thoughts about the New Coronavirus Syndrome and its Transmission
  • Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB
  • The Weak Correlation Between Antibiotic Action and Mortality
  • FDA Needs Radical Reform
  • The Letermovir Top-Line Results are Out – Or Are They?
  • The CDC and Spectinomycin
  • GC Therapy –  Shooting for the Stars
  • Efficacy and Treatment Duration: Where is the Tipping Point?
  • QIDP, a Liberal Hand-Out from FDA
  • CMV Connections: Paul-Bunnell Negative Mononucleosis and ‘Changelings’

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Allphase Pharma Consulting aminoglycoside antibiotic blog Avelox Bayer Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA FDA Guidance fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline Orbactiv oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • Email
Copyright © 2021 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: